Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
暂无分享,去创建一个
S. Shoelson | D. Cai | L. Hansen | Jongsoon Lee | M. Yuan | Daniel F Frantz | P. A. Meléndez | Steven E Shoelson
[1] W. Frontera,et al. IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice , 2004, Cell.
[2] G. Cline,et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. , 2004, Diabetes.
[3] K. Rajewsky,et al. Conditional disruption of IκB kinase 2 fails to prevent obesity-induced insulin resistance , 2004 .
[4] J. Hoofnagle,et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.
[5] K. Rajewsky,et al. Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. , 2004, The Journal of clinical investigation.
[6] M. Desai,et al. Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.
[7] L. Tartaglia,et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.
[8] J. Capeau,et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. , 2003, Biochemical and biophysical research communications.
[9] U. Smith,et al. Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-α, Overexpressed in Human Fat Cells from Insulin-resistant Subjects* , 2003, Journal of Biological Chemistry.
[10] S. Shoelson,et al. Inflammation and the IKKβ/IκB/NF-κB axis in obesity- and diet-induced insulin resistance , 2003, International Journal of Obesity.
[11] G. Hotamisligil,et al. Inflammatory pathways and insulin action , 2003, International Journal of Obesity.
[12] T. Zimmers,et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. , 2003, Diabetes.
[13] B. Neuschwander‐Tetri,et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.
[14] L. Kuller,et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. , 2003, American journal of physiology. Endocrinology and metabolism.
[15] E. Freedland,et al. Inflammation and its relationship to insulin resistance, type 2 diabetes mellitus, and endothelial dysfunction. , 2003, Metabolic syndrome and related disorders.
[16] Joachim Spranger,et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.
[17] A. Mokdad,et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.
[18] W. Ebstein. Invited comment on W. Ebstein: On the therapy of diabetes mellitus, in particular on the application of sodium salicylate. , 2002, Journal of molecular medicine.
[19] S. Shoelson. JMM – Past and Present , 2002, Journal of Molecular Medicine.
[20] A. Häkkinen,et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.
[21] K. Petersen,et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. , 2002, The Journal of clinical investigation.
[22] S. Haffner,et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.
[23] U. Visco-Comandini,et al. Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.
[24] Michael Karin,et al. Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.
[25] G. Shulman,et al. Prevention of fat-induced insulin resistance by salicylate. , 2001, The Journal of clinical investigation.
[26] J. Manson,et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.
[27] A. Fischer,et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. , 2001, Blood.
[28] J. Radziuk,et al. Insulin sensitivity and its measurement: structural commonalities among the methods. , 2000, The Journal of clinical endocrinology and metabolism.
[29] D. Moller. Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes , 2000, Trends in Endocrinology & Metabolism.
[30] A. Häkkinen,et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. , 2000, Diabetes.
[31] Nanxin Li,et al. [25] Signaling pathways leading to nuclear factor-κB activation , 2000 .
[32] D. Moller. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. , 2000, Trends in endocrinology and metabolism: TEM.
[33] M. Karin,et al. Signaling pathways leading to nuclear factor-kappa B activation. , 2000, Methods in enzymology.
[34] Michael Karin,et al. Positive and Negative Regulation of IκB Kinase Activity Through IKKβ Subunit Phosphorylation , 1999 .
[35] M. Mann,et al. IκB Kinase (IKK)-Associated Protein 1, a Common Component of the Heterogeneous IKK Complex , 1999, Molecular and Cellular Biology.
[36] M. A. Crook,et al. Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.
[37] S. Ito,et al. Interleukin 1β and interleukin 6, but not tumor necrosis factor α, inhibit insulin‐stimulated glycogen synthesis in rat hepatocytes , 1998 .
[38] Zhaodan Cao,et al. NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176 , 1998 .
[39] D. Goeddel,et al. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] S. Ito,et al. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. , 1998, Hepatology.
[41] C. Burant,et al. Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.
[42] Seamus J. Martin,et al. Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.
[43] D. Green,et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. , 1996, Science.
[44] M. Karin,et al. Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B , 1995, Molecular and cellular biology.
[45] M. Papa,et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. , 1993, The Journal of biological chemistry.
[46] B. Spiegelman,et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.
[47] J. Abrams,et al. Strategies of Anti‐Cytokine Monoclonal Antibody Development: Immunoassay of IL‐10 and IL‐5 in Clinical Samples , 1992, Immunological reviews.
[48] J. Abrams,et al. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. , 1990, Journal of immunology.
[49] R. Palmiter,et al. Introns increase transcriptional efficiency in transgenic mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.